US FDA asks firms to check quality of glass drug vials
This article was originally published in SRA
The US Food and Drug Administration has expressed concern over several recent incidents of injectable drugs, filled in small-volume glass vials, being recalled due to the formation of glass lamellae (ie glass fragments). The agency is asking manufacturers of these products to re-examine their supplier quality management programme with glass vial manufacturers to prevent such incidents1.
You may also be interested in...
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.